A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.
Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
LOXO-305 treatment of heavily pretreated CLL/SLL resulted in durable, high response rates in a phase 1/2 trial.
The average spending per hospitalization during the course of 5 years was higher for survivors of NHL compared with controls ($16,950 vs. $13,474).
Researchers sought to determine how and which factors contribute to healthcare utilization by patients with AML at the end of life.
Open-label, randomized clinical trial sought to determine noninferiority of subcutaneous and IV infusion cytarabine in young adults with AML.
Researchers identify factors that influence relapse after HSCT in patients with acute lymphoblastic leukemia.
Comparison of results from 2 phase 3 studies of combination therapies are presented at ASH 2020.
Combination therapy positively influenced overall survival rates, dyspnea, and fatigue through 48 weeks in this patient population.
Axi-cel demonstrated significant clinical benefit as a first-line treatment for patients with high-risk large B-cell lymphoma.
A retrospective analysis compared survival rates after allogeneic hematopoietic stem cell transplantation in men with those of women.
An analysis of data from SEER-Medicare database compared end-of-life care, including hospitalizations and use of hospice, between patients with solid tumors and hematologic malignancies.
Researchers present data regarding end-of-life care management in patients with multiple myeloma.
The bispecific CAR-T therapy targets CD20 and CD19.
Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.
Ibrutinib was associated with a longer duration until second-line treatment, regardless of risk status, compared with CIT among patients with CLL.
Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.
A CAR-T therapy for myeloma that is manufactured using a unique process showed clinical activity and appeared safe, even in the outpatient setting.